Synthetic cannabinoidsK2/Spice

Clinical contraindication: Relative; Substantial clinical concern; the literature treats it as a reason for caution or deferral.
Best available evidence: Case reports
Half-life: Not recorded

Named in state rules?

CONot named

ORNot named

NMPending

Cite asPsilodex: synthetic-cannabinoids · v2026.10.02

Clinical data and state rules are separate facts. Both are shown; neither is a decision.

01 Interaction with psilocybin

Poison-center reports list tachycardia, raised blood pressure, seizures, hallucinations and agitation; product content and potency vary widely. No psilocybin-specific data.

Human data with psilocybin: Case reports or surveys only

Evidence types on this record

CRCase reports or online surveys

02 Pharmacology relevant to psilocybin

2 listed · counted on reports

Raises blood pressure or heart rate: Raises blood pressure or heart rate. Psilocybin raises both for several hours, so the effects can add. Sources [1]
Lowers seizure threshold or carries seizure risk: Makes a seizure more likely, or has been linked to seizures. Sources [1]

03 State rules

Plain-language summary · official text governs

CO4 CCR 755-1

Not named

No provision names this medication or its class.

Colorado · checked 2026-09-30

OROAR 333-333

Not named

No provision names this medication or its class.

Oregon · checked 2026-09-30

NM7.35.3 NMAC (proposed)

Pending

New Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.

New Mexico · checked 2026-09-30

04 Conditions to ask about

None linked

No condition named in state rules is linked to this medication.

05 Sources

US Drug Enforcement Administration. Drug Fact Sheets (per-entry link).

Report an error in this record →